Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841748 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
A Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Head and Neck, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT02841748: Active Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Head and Neck, sponsored by University of Chicago.
NCT02841748 is a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Head and Neck that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 100 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02841748, a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of the Head and Neck, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.
Primary Outcome
Time from randomization to disease progression or death from any cause.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
Study Locations (4)
Illinois
- Rush University Medical Center - Chicago
- University of Chicago Medical Center - Chicago
Georgia
- Emory University Winship Cancer Institute - Atlanta
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2026-06-25 |
| Phase | Phase 2 |
What the registry record for NCT02841748 still lists
NCT02841748 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02841748 reports a single indexed study location in Illinois, Georgia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02841748 about?
NCT02841748 is a clinical study titled "A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study". A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.
What is the current status of trial NCT02841748?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-05-10. Estimated completion is 2026-06-25.
What conditions does trial NCT02841748 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT02841748?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG).
Who is sponsoring clinical trial NCT02841748?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02841748 being conducted?
This trial has 4 study locations across Georgia, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02841748's enrollment target sits among peer trials
100 82nd of 250 higher than 165 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI